Dec., 24, 2015, Mumbai, India: Market Reports on China presents the report, on “China Ioversol Market Investigation Report [2010-2019]”. In recent years, contrast agent market in China has maintained a growth of about 20%. Ioersol, in particular, has reported a growth of 60%. Currently, ioersol is used in many hospitals due to its cheap price and good quality.
As a non-ionic contrast medium, ioversol featuring low toxicity and few effects is mainly used to enhance the contrast of blood vessels in medical imaging. Containing iodine, ioversol works based on x-ray attenuation. "http://www.marketreportsonchina.com/life-sciences-market-research-reports-17712/investigation-china-ioversol.html"
Contrast medium is commonly used to enhance the visibility of blood vessels and body cavity. And its application area has expanded from X-ray/CT imaging to ultrasound scattering and magnetic resonance imaging. In recent years, contrast agent market in China has maintained a growth of about 20%. Ioersol, in particular, has reported a growth of 60%. Currently, ioersol is used in many hospitals due to its cheap price and good quality.
Ioversol enjoys a vast demand with sales value of ioversol rising from less than CNY 30 million in 2005 to over CNY 200 million in 2014 and CAGR during this period reaching 27%. Mallinckrodt Medical Inc.(Canada), Mallinckrodt Medical Inc.(USA) and Jiangsu Hengrui Medicine Co., Ltd mainly occupy the market, among which Jiangsu Hengrui Medicine Co., Ltd had the largest market share of over 80% for sales value in 2014.
Readers can get at least the following information through this report:
-market size of ioversol in China
-competitive landscape of ioversol market in China
-price of ioversol made by different enterprises in China
-market outlook of ioversol in China
The author suggests the following groups of people purchase this report:
-drug makers
-investors/research institutions interested in Chinese medicine market
-any interest...